Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Autoimmunity, and Virology Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD4 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CD4 Products |
| Gene Delivery | CD4 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and cell-based flow cytometry assays. |
View CD4 Products |
| Benchmark Ab | Anti-CD4 (Sequence of Ibalizumab / Zanolimumab) Recombinant positive control antibodies for binding and functional assays. |
View CD4 Products |
| Validator | CD4 siRNA Set For target knockdown verification and specificity profiling. |
View CD4 Products |
| Related Target A | gp120 Viral envelope glycoprotein; critical for HIV-1 entry assays and CD4-gp120 binding inhibition screening. |
View gp120 Products |
| Related Target B | LAG3 Immune checkpoint co-receptor structurally homologous to CD4; essential for selectivity and off-target safety screening. |
View LAG3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Domain-Specific Epitope Mapping (Domain 1 vs. Domain 2 binding) | Truncated and domain-specific CD4 recombinant proteins available, sequence verified and HEK293 expressed. |
| Off-Target Homology Screening (LAG3/MHC-II cross-reactivity) | High-purity homolog panels (LAG3, MHC Class II complexes) strictly verified by mass spectrometry. |
| Lack of Standardized Reference Controls | Sequence-accurate Clinical Benchmark Antibodies (Ibalizumab and Zanolimumab biosimilars) included |
| False Positive Signals in Cell Binding | Sequence-verified siRNA knockdown tools included for cellular specificity validation |
Live CD4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CD4 is undergoing a significant renaissance. Originally established as a target for immunosuppression in autoimmune diseases and a receptor target for HIV entry inhibitors (e.g., Ibalizumab), CD4 is now being actively pursued in oncology. The focus has shifted toward targeting CD4+ T-cell malignancies (such as Cutaneous T-Cell Lymphoma, CTCL) using Antibody-Drug Conjugates (ADCs) and CAR-T cell therapies. Additionally, modulating CD4+ Regulatory T cells (Tregs) in the tumor microenvironment represents a major frontier in immunotherapy. As next-generation multispecifics and ADCs enter development, precise epitope targeting and functional validation remain critical to avoiding systemic T-cell depletion and cytokine release syndrome.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Academic Institutions, Biotech Startups | T-Cell Lymphomas (CTCL, PTCL) | Internalization Assay (Need high-purity, native-glycosylation CD4 ECD-Fc for kinetic analysis) |
| Bispecific / Multispecific Ab | Biopharma Innovators | Autoimmune Diseases, HIV-1 | Simultaneous binding kinetics (Need stable CD4 and co-receptor proteins for SPR/BLI) |
| Monoclonal Antibody (mAb) | TaiMed Biologics, Immuno-oncology developers | HIV-1 Infection, Treg Modulation | Epitope mapping & block assays (Need domain-truncated CD4 proteins and benchmark biosimilars) |